Some studies suggest that luminal breast cancer harboring KMT2C mutation can be treated with the EZH2 inhibitor GSK126, which mitigates dysregulated gene expression patterns and aberrant cell proliferation [158,168]. Here, EZH2 is linked to breast carcinoma.